Outcomes of Novel Hormonal Therapies in Men With Advanced Prostate Cancer by Treating Specialist
The specialty of the physician prescribing a novel hormonal therapy was not associated with the risk of a cardiometabolic adverse event. Further, management by a urologist did not adversely affect costs to patients or adherence.
Authors
- Brent K. Hollenbeck (ORCID: https://orcid.org/0000-0003-4840-1260)
- Kassem Faraj (ORCID: https://orcid.org/0000-0002-2130-0446)
- Avinash Maganty (ORCID: https://orcid.org/0000-0001-6436-6667)
- Megan E.V. Caram (ORCID: https://orcid.org/0000-0003-1597-5428)
- Vahakn B. Shahinian (ORCID: https://orcid.org/0000-0003-3280-7821)
- Mary Oerline (ORCID: https://orcid.org/0000-0002-0264-6951)
- Samuel R. Kaufman
Institutions
- University of Michigan (US)
- Massachusetts General Hospital (US)
- VA Ann Arbor Healthcare System (US)
- Michigan Medicine (US)
- VA Center for Clinical Management Research (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1002/cam4.71219
- Citations
- 1
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- National Cancer Institute